Archon Biosciences
Archon Biosciences develops geometrically tunable protein therapeutics called Antibody Cages (AbCs), which integrate antibody affinity and specificity with generative protein design to target pathways inaccessible to other technologies. Its platform uses AI-driven structural engineering to create biologics with precise control over distribution, engagement, and function for improved treatment of disease. The organization aims to solve challenging drug discovery problems by advancing new classes of biologic medicines.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2023 Seattle business license
- Type
- Corporation Seattle business license
- Employees
- 26
- Registered name
- Archon Biosciences Inc Seattle business license
- Stage
- Seed
Is this your organization? Claim it
UW Institute for Protein Design and Nvidia open-source RFD4-Proteina model, claims 5–10× faster designs and higher success rates
The UW Medicine Institute for Protein Design and Nvidia released RFD4-Proteina, an open-source AI model that co-designs protein sequences and atomic structures and reportedly produces candidates 5–10× faster with 5–10× higher benchmark success rates. A UW student used the model to design an improved pesticide-degrading enzyme in days, and lab tests confirmed the model's outputs behaved as expected.
UW Institute for Protein Design and Nvidia unveil RFD4-Proteina, an open-source AI model for designing functional proteins after Jensen Huang GPU grant
UW’s Institute for Protein Design and Nvidia jointly released RFD4-Proteina, an open-source AI model for designing proteins with specific functions, developed after a major GPU grant from Nvidia CEO Jensen Huang’s foundation. IPD and director David Baker say the model is faster, more efficient, and could enable new medical, sustainability, and biotechnology applications.
Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model
Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.
See all 6 news stories about Archon Biosciences.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
George Ueda Chief Technology Officer, Co-Founder
-
James Lazarovits Chief Executive Officer, Co-Founder